News for Merck & Co., Inc. (MRK.SN)

Key Takeaways: Merck's (MRK) shares rose as Summit Therapeutics shared promising Phase 3 trial results for a competing lung cancer drug. Analysts set a o

Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene ex

**media[605892]**

BMO Capital Markets has adjusted its price target for Merck (MRK), now setting it at $82, reduced from the previous target of $89. The decision follows Merck's

**media[605613]**

Key Insights for Investors: Merck & Co. (MRK) anticipates significant challenges ahead, including a projected $200 million loss in 2025 due to tariffs. D

Merck & Co. reports robust Q1 2025 revenue with significant contributions from KEYTRUDA. Analysts set an average one-year target price of $110.25 for Merck,

The following slide deck was published by Merck & Co., Inc.

Merck & Co., Inc. (NYSE:MRK) Q1 2025 Earnings Conference Call April 24, 2025 9:00 AM ETCorporate ParticipantsPeter Dannenbaum - Senior Vice President,...

Biopharmaceutical company Merck reported Thursday a net profit for the first quarter that grew 7 percent from last year, primarily reflecting improved gross margins and lower restructuring costs, despite a 2 percent sales drop and negative foreign exchange impact.

Biopharmaceutical company Merck reported Thursday a net profit for the first quarter that grew 7 percent from last year, primarily reflecting improved gross margins and lower restructuring costs, despite a 2 percent sales drop and negative foreign exchange impact.

Merck (MRK) outperformed expectations in its latest earnings report, with non-GAAP earnings per share of $2.22, $0.08 higher than anticipated. The company's

Summary Highlights: Merck (MRK) exceeded Q1 2025 expectations with $15.5 billion in sales, despite a decline from last year. Keytruda sales rose by 4% re

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2025. ”œOur company made str

The company has updated its financial projections for the fiscal year 2025, now forecasting revenue between $64.1 billion and $65.6 billion. This aligns closely

PR NewswireCHENGDU, China, April 24, 2025 CHENGDU, China, April 24, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) announ

CHENGDU, China, April 24, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) announced that it will present results from six Kelun-led clinical studies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago from May 30 to June 3. Results include data from its TROP2 antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT), anti-PD-L1 mAb tagitanlimab, and RET inhibitor KL590586 (A400/EP0031). The abstracts for these studies will be published on the ASCO's official website on May 22, 2025, local time.

Merck (MRK) is expected to report a slight decline in first-quarter earnings. Analyst forecasts suggest a potential 40.30% upside in stock price. Mer

We recently published a list of 20 Best Stock To Buy According to Marjorie Taylor Greene. In this article, we are going to take a look at where Merck & Co., Inc.